---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-178592"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T15:07:48.878898+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Zymeworks appoints Carlos Campoy to board; director Natalie Sacks resigns effective June 30, 2023

## Summary
- Carlos Campoy appointed as Class I director effective June 30, 2023, term expiring at 2025 AGM.
- Campoy receives initial grant of 50,000 common shares as part of standard non-employee director compensation.
- Natalie Sacks resigned effective June 30, 2023; resignation not due to any disagreement with the company.
- Campoy joins audit and nominating/corporate governance committees; Kelvin Neu named chair of R&D committee.

## SEC filing metadata
- accession: 0001193125-23-178592
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312523178592/0001193125-23-178592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312523178592/d307320d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-178592
- JSON: https://secwatch.observer/filing/0001193125-23-178592.json
- Plain text: https://secwatch.observer/filing/0001193125-23-178592.txt

## Key facts
- Executive change
  Carlos Campoy was appointed as Director at Zymeworks Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Mr. Carlos Campoy as a director of the Company, effective as of June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000119312523178592/0001193125-23-178592-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.